Non-Hodgkin lymphoma - management overview
NHL · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A heterogeneous group of lymphoid malignancies ranging from indolent (e.g. follicular) to aggressive (e.g. diffuse large B-cell). Management is subtype-specific; aggressive forms are potentially curable while many indolent ones are treated for control.
Red flags
- Spinal cord compression or CNS involvement
- SVC obstruction / airway compromise
- Tumour lysis syndrome
- Rapidly enlarging mass (transformation)
- B symptoms with rapid deterioration
Assessment
Differential diagnosis
- Hodgkin lymphoma
- Reactive/infective lymphadenopathy
- Chronic lymphocytic leukaemia
- Metastatic carcinoma
- Autoimmune lymphadenopathy
- Plasma cell neoplasm
Investigations
- Excisional/core lymph node biopsy with immunophenotyping and molecular studies
- FBC, LDH, renal and liver function, urate
- HIV and hepatitis B/C serology (reactivation risk with rituximab)
- PET-CT and/or CT for staging
- Bone marrow biopsy where indicated
- Cardiac assessment before anthracyclines
Management
- Obtain adequate tissue and precise histological subtyping
- Stage with imaging and assess performance status and prognostic index (e.g. IPI/FLIPI)
- Classify as aggressive or indolent to set treatment goals (cure vs control)
- Screen hepatitis B before rituximab and give antiviral prophylaxis if positive
- Treat diffuse large B-cell lymphoma with R-CHOP immunochemotherapy aiming for cure
- Give tumour lysis prophylaxis in bulky/aggressive disease
- Manage indolent follicular lymphoma with watch-and-wait if asymptomatic, or rituximab-based therapy when treatment indicated
- Use CNS prophylaxis in high-risk aggressive lymphoma
- Treat relapsed/refractory aggressive disease with salvage chemotherapy, autologous transplant, bispecific antibodies or CAR-T
- Provide maintenance, surveillance and survivorship care per subtype
Drugs & doses
R-CHOP: rituximab 375 mg/m2 + cyclophosphamide 750 mg/m2 + doxorubicin 50 mg/m2 + vincristine 1.4 mg/m2 (cap 2 mg) IV day 1 + prednisolone 100 mg PO days 1-5, every 21 days
Bendamustine 90 mg/m2 IV days 1-2 + rituximab (indolent lymphoma)
Rituximab maintenance 375 mg/m2 every 2-3 months (follicular lymphoma)
Allopurinol/rasburicase for tumour lysis prophylaxis
Disposition
Haematology/oncology management; urgent admission for oncological emergencies; subtype-specific long-term follow-up.
Complications & pitfalls
- Tumour lysis syndrome
- Hepatitis B reactivation
- Anthracycline cardiotoxicity
- Transformation of indolent to aggressive lymphoma
- Immunosuppression/infection
- Relapse
Exam pearls
- Precise subtyping dictates whether the aim is cure or disease control
- Screen and cover hepatitis B before rituximab
- Asymptomatic indolent lymphoma can be safely observed
- CAR-T and bispecific antibodies are changing relapsed aggressive lymphoma outcomes
- Rising LDH and rapid growth suggest aggressive or transformed disease
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.